Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1453 studies found for:    Open Studies | "Lymphatic Diseases"
Show Display Options
Download search resultsDownload the search results for:
Open Studies | "Lymphatic Diseases" (1453 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting National Lymphatic Disease and Lymphedema Registry
Condition: Lymphedema
Intervention:
2 Recruiting Study of Autoimmune Lymphoproliferative Syndrome (ALPS)
Conditions: Autoimmune Disease;   Lymphatic Disease;   Lymphoproliferative Disorder;   Canale-Smith Syndrome
Intervention:
3 Recruiting Sildenafil for the Treatment of Lymphatic Malformations
Conditions: Lymphatic Malformations;   Lymphatic Diseases
Interventions: Drug: Sildenafil 20 mg tablets;   Other: Placebo tablets (resembling Revatio)
4 Recruiting Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
Conditions: Lymphatic Diseases;   Hematopoietic Malignancy
Intervention: Biological: Umbilical Cord Blood (UCB)
5 Recruiting Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders
Conditions: Lymphangiomatosis;   Lymphedema;   Lymphangiectasia;   Pulmonary Lymphangiectasia
Intervention:
6 Unknown  Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders
Condition: Lymphedema
Intervention: Drug: near-infrared fluorescence imaging
7 Recruiting E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma
Condition: Peripheral T-Cell Lymphoma
Intervention: Biological: denileukin diftitox (E7777)
8 Recruiting A Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Intervention: Drug: Brentuximab vedotin
9 Recruiting Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Non-hodgkin Lymphoma or Multiple Myeloma
Conditions: Non-Hodgkin Lymphoma;   Multiple Myeloma
Intervention: Drug: ABT-199
10 Available Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Bone Marrow Failure;   Hemoglobinopathy;   Immune Deficiency;   Osteopetrosis;   Cytopenias;   White Blood Cell Abnormalities;   Red Blood Cell Abnormalities
Intervention: Biological: CD34+ enriched, T Cell Depleted donor stem cell product
11 Recruiting Zevalin-Beam for Aggressive Lymphoma
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: Yttrium Y 90 Ibritumomab tiuxetan;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Procedure: Autologous Hematopoietic Stem Cell Transplantation
12 Unknown  TREatment of degeNerative and Neoplastic Diseases With Rituximab
Condition: Diffuse Large B Cell Lymphoma
Intervention: Biological: Rituximab
13 Recruiting Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
Conditions: Solid Tumors;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Glioblastoma Multiforme;   Oligodendroglioma;   Hepatocellular Carcinoma;   Diffuse Large B-cell Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: CC-122 HCL
14 Recruiting This Trial is a Safety and Feasibility Study of Combination of State of the Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Testicular Diffuse Large B-cell Lymphoma
Condition: Primary Testicular Diffuse Large B-cell Lymphoma
Intervention: Drug: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate
15 Unknown  Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC)
Conditions: Multiple Myeloma;   Plasma Cell Dyscrasia;   Lymphoma;   Lymphoproliferative Disorders
Intervention: Drug: Plerixafor and G-CSF
16 Recruiting Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease
Condition: Erdheim-Chester Disease
Intervention:
17 Unknown  Osteonecrosis in Children With Acute Lymphoblastic Leukemia
Conditions: Osteonecrosis;   Acute Lymphoblastic Leukemia
Intervention:
18 Recruiting Cellular Immunotherapy After Cyclophosphamide in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia
Interventions: Drug: cyclophosphamide;   Biological: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells;   Other: laboratory biomarker analysis
19 Unknown  Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma
Condition: T Cell Lymphoma
Intervention: Drug: endostar and CHOP
20 Recruiting Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
Conditions: Adult B Acute Lymphoblastic Leukemia;   Chronic Lymphocytic Leukemia;   Cutaneous B-Cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   HIV Infection;   Intraocular Lymphoma;   Multicentric Angiofollicular Lymphoid Hyperplasia;   Nodal Marginal Zone Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Plasma Cell Myeloma;   Small Intestinal Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenstrom Macroglobulinemia
Interventions: Drug: Ibrutinib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years